Skip to main content
OpenTrials
Completed

NCT Number: NCT03653910

Effect-site Concentration of Remifentanil for Double-lumen Tubes Intubation: Airtraq VS Macintosh Laryngoscope

The 50% effective concentration of remifentanil by target controlled infusion was not determined for inhibiting the haemodynamic response during double-lumen tube (DLT) intubation. Previous study showed that Airtraq videolaryngoscope provided more stable haemodynamics than Macintosh for double-lumen tube intubation. In this study, the investigators will compare the 50% effective concentration of remifentanil between Airtraq videolaryngoscope and Macintosh laryngoscope for inhibiting haemodynamic responses during DLT intubation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemodynamic Instability Intubation Complication

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tongji Hospital, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

About this study

Dixon "up-and-down" method was used to determine 50% effective concentration of remifentanil by target controlled infusion for inhibiting the haemodynamic responses during DLT intubation with Airtraq videolaryngoscope or Macintosh laryngoscope.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

s:

  • American Society of Anesthesiologists physical status of I-II
  • Patients aged 18-65 years
  • BMI 18-35 kg/m2
  • Elective pulmonary surgery under general anesthesia to double-lumen tubes intubation
  • Mallampati classifications Ⅰ-Ⅱ

Exclusion criteria

s:

  • Emergency operation
  • Anticipated difficult airway or history of intubation difficulties
  • Be allergic to any of the drugs used in the experiment, or have a history of drug allergy
  • Preoperative use of analgesic, sedative and other drugs
  • Uncontrolled hypertension and heart disease
  • Have a history of heavy smoking and alcohol abuse, serious drug abuse, and severe systemic infections
  • There are severe mental and nervous system symptoms, and patients cannot cooperate with the study, such as language comprehension disorder, mental illness, etc
  • Other clinical trials were conducted within 3 months prior to inclusion in the study

Treatment and study plan

Airtraq

Device

Airtraq is a kind of videolaryngoscope for intubation

Macintosh

Device

Macintosh is a traditional laryngoscope for intubation

Primary outcomes

  1. Remifentanil TCI effect site concentration

    Time frame: through study completion, an average of 20 min

    preestablish remifentanil TCI effect site concentration(ng/ml)

Secondary outcomes

  1. mean arterial pressure

    Time frame: at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation

    mean arterial pressure in mmHg

  2. heart rate

    Time frame: at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation

    heart rate in bpm

  3. Narcotrend index

    Time frame: at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation

    Narcotrend index in Arabic numerals

Sponsors and collaborators

Lead sponsor

Huazhong University of Science and Technology

Other

Registry information

Official study title

Effect-site Concentration of Remifentanil for Inhibiting Cardiovascular Responses to Double-lumen Tube Intubation With Airtraq Videolaryngoscopy: a Comparative Study With Macintosh Laryngoscopy

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 31, 2018
Registry last updated
May 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.